HER2+ BC had a higher frequency of HER2-E subtype (47 vs. 7.1% in HER2-negative tumors), with a lower frequency of luminal A (10.7 vs. 39%) and basal-like subtypes (14.1 vs. 23.4%). Here, ERBB2 is linked to breast cancer.